Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Group sales rose 4% to CHF 50.6 billion. Despite high investments in the launch of new products and product development, core EPS grew faster than sales (+5%). Core EPS growth reflects the good underlying business performance and an impact from changes to the Group's Swiss pension plans.

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2016 and provided 2017 financial guidance. Pfizer manages its commercial operations through two distinct businesses: Pfizer Innovative Health (IH) (formerly the Innovative Products business) and Pfizer Essential Health (EH) (formerly the Established Products business).

University of Oxford and Novo Nordisk today announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research centre on the premises of the University of Oxford.

CUBE's goal is to push the envelope on innovation. Making change and innovation happen in the industry is a tough challenge that takes knowledge, creativity, time and also courage. No Equity. No obligations. No strings attached. If your startup is outstanding, your products are desperately needed by the industry and the best of all qualifiers, CUBE will give you one million euros in cash.

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2016, which were highlighted by strong sales for key products Opdivo and Eliquis, regulatory approvals for Opdivo in the U.S. and Europe, and strategic transactions in oncology and fibrosis that further strengthened the company's pipeline.

AstraZeneca today announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of paediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol. The FDA's decision was based on the evaluation of trials conducted in children with asthma aged six up to 12 years in response to a Written Request

Abbott (NYSE: ABT) has announced that fourth-quarter 2016 worldwide sales of $5.3 billion increased 2.8 percent on a reported basis, including an unfavorable 1.0 percent effect of foreign exchange, and increased 3.8 percent on an operational basis. Full-year 2016 worldwide sales increased 2.2 percent on a reported basis and 4.8 percent on an operational basis.